Department of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, The University of Toledo Toledo, OH, USA.
Front Immunol. 2012 Jan 2;2:82. doi: 10.3389/fimmu.2011.00082. eCollection 2011.
Understanding rheumatic diseases from the perspective of chemokine biology has shaped and will continue to shape our approach for targeted drug design. Among different kinds of chemokines, fractalkine/CX3CL1 has been found to play an important role in inflammation, portraying unique functional, and structural characteristics. This review summarizes the emerging role of fractalkine/CX3CL1 from a functional and clinical perspective and provides evidence to validate it as a potential therapeutic target in rheumatic diseases such as rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, scleroderma, as well as diseases related to vascular inflammation. From this, recent studies investigating potential therapeutic agents against fractalkine/CX3CL1's role in pathology have shown promise.
从趋化因子生物学的角度理解风湿性疾病已经并将继续影响我们的靶向药物设计方法。在不同类型的趋化因子中， fractalkine/CX3CL1 已被发现在炎症中发挥重要作用，具有独特的功能和结构特征。本综述从功能和临床角度总结了 fractalkine/CX3CL1 的新作用，并提供了将其作为类风湿关节炎、干燥综合征、系统性红斑狼疮、硬皮病以及与血管炎症相关疾病等风湿性疾病潜在治疗靶点的证据。在此基础上，最近研究调查了针对 fractalkine/CX3CL1 在病理学中作用的潜在治疗药物，显示出了一定的前景。
